Table 1.

Distribution of CCR5 genotypes in the study cohort. Frequencies of CCR5 genotypes and the CCR5 allele prevalence in patients with tick-borne encephalitis (TBE) stratified according to clinical variables and in healthy controls from the same area. The frequencies of wt/wt and combined wt/Δ32 and Δ32/Δ32 genotypes, as well as wt and Δ32 allele prevalence, did not differ significantly between the groups.

Group	CCR5 Genotype Prevalence a			CCR5 Allele Prevalence
	wt/wt	wt/ Δ32	Δ32/ Δ32	(wt/Δ32 Allele)
Healthy controls (n = 265)	212 (82.5%)	41 (16.0%)	4 (1.6%)	0.905/0.095
TBE (n = 205)	166 (81.0%)	36 (17.6%)	3 (1.5%)	0.898/0.102
Clinical presentation
meningitis (M) (n = 109)	88 (80.7%)	19 (17.4%)	2 (1.8%)	0.894/0.106
meningoencephalitis (ME) (n = 77)	63 (81.8%)	13 (16.9%)	1 (1.3%)	0.903/0.097
meningoencephalomyelitis (MEM) (n = 19)	15 (78.9%)	4 (21.1%)	0 (0.0%)	0.895/0.105
Severity of ME/MEM
mild (n = 43)	36 (83.7%)	6 (14.0%)	1 (2.3%)	0.907/0.093
moderate (n = 36)	30 (83.3%)	6 (16.7%)	0 (0.0%)	0.917/0.083
severe (n = 17)	12 (70.6%)	5 (29.4%)	0 (0.0%)	0.853/0.147
Consciousness abnormalities
absent (n = 155)	128 (82.6%)	24 (15.4%)	3 (1.9%)	0.903/0.097
present (n = 50):	38 (76.0%)	12 (24.0%)	0 (0.0%)	0.880/0.120
mild (n = 33)	26 (78.8%)	7 (21.2%)	0 (0.0%)	0.894/0.106
moderate (n = 9)	6 (66.7%)	3 (33.3%)	0 (0.0%)	0.833/0.167
severe (n = 8)	6 (75.0%)	2 (25.0%)	0 (0.0%)	0.875/0.125
Paresis
absent (n = 187)	152 (81.3%)	32 (17.1%)	3 (1.6%)	0.898/0.102
present (n = 18)	14 (77.8%)	4 (22.2%)	0 (0.0%)	0.889/0.111
Cerebellar syndrome
absent (n = 166)	134 (80.7%)	30 (18.1%)	2 (1.2%)	0.898/0.102
present (n = 39)	32 (82.1%)	6 (15.4%)	1 (2.6%)	0.897/0.103
Disease course
monophasic (n = 110)	87 (79.1%)	21 (19.1%)	2 (1.8%)	0.886/0.114
biphasic (n = 92)	78 (84.8%)	13 (14.1%)	1 (1.1%)	0.918/0.082

^a number of cases (frequency of a genotype in %); wt—wild type.